RIO DE JANEIRO
For four decades, living with HIV has meant one non-negotiable ritual: swallowing a pill, every single day, for the rest of your life. Miss too many doses, and the virus can come roaring back, mutate around your medication, and undo years of careful treatment. That daily grind — quiet, relentless, and for many patients deeply stigmatizing — has defined what it means to manage HIV since the first effective antiretrovirals arrived in the 1990s.
This week, at the AIDS 2026 conference in Rio de Janeiro, two of the biggest names in HIV research, Gilead Sciences and Merck, presented interim data suggesting that daily ritual might finally be optional. Their investigational drug — a single tablet combining Merck's islatravir with Gilead's lenacapavir, dosed just once a week — met its primary goal in not one but two major Phase 3 trials, holding the virus in check just as effectively as the daily pills patients have relied on for years.
If the drug clears regulatory review, doctors say it could mark the most significant simplification of HIV treatment since the introduction of single-tablet daily regimens two decades ago — a shift that could ripple out from wealthy countries with easy pharmacy access to the parts of the world where HIV still kills the most people and daily adherence is hardest to sustain.
The Science Behind the Once-a-Week Pill
The new regimen pairs two drugs that already carry serious scientific pedigree individually. Islatravir is a "next-generation" nucleoside analog — the same broad drug class that includes some of the oldest antiretrovirals ever developed — but engineered with multiple mechanisms of action, including a novel ability to block HIV's reverse transcriptase enzyme through a process called translocation inhibition, which effectively jams the machinery the virus uses to convert its genetic material and hijack a host cell.
Lenacapavir is arguably the more revolutionary half of the pairing. It's a first-in-class capsid inhibitor, meaning it attacks the protein shell — the capsid — that HIV uses to protect and transport its genetic payload inside a cell. Because it disrupts the virus at multiple stages of its lifecycle rather than a single step, lenacapavir has already made headlines in its injectable form as a twice-yearly HIV prevention shot. Combining it with islatravir in a once-weekly oral tablet represents a new strategy: instead of extending dosing intervals through an injection given in a clinic, patients get a pill they can take at home, just far less often than they're used to.
Together, islatravir and lenacapavir were tested in two large, multi-country, double-blind, active-controlled Phase 3 trials known as ISLEND-1 and ISLEND-2. Both trials enrolled adults already living with HIV whose viral load had been successfully suppressed to below 50 copies per milliliter of blood — the clinical definition of an undetectable, non-transmissible viral load — for at least six months on a standard daily regimen. In ISLEND-1, that standard was Gilead's own blockbuster daily pill, Biktarvy, one of the most widely prescribed HIV treatments in the world. Patients in both studies were then randomized either to stay on their daily pill or switch to the experimental once-weekly islatravir/lenacapavir tablet.
At the Week 48 mark — the primary endpoint of both trials — researchers reported that the once-weekly regimen was "statistically non-inferior" to the daily comparator drugs. In plain terms: patients who switched to taking a pill once a week maintained viral suppression just as reliably as those who kept taking a pill every single day. Gilead and Merck said the safety profile of the weekly combination was generally similar to the daily regimens it was tested against, with no new safety concerns identified in the data reported so far. Full detailed results, including the granular efficacy and safety breakdowns, are scheduled to be unveiled in late-breaking sessions at AIDS 2026 this week, after being previewed in the conference's official press program.
Why Every Day Matters — And Why It's So Hard
To understand why a once-a-week pill is such a big deal, you have to understand just how unforgiving daily HIV treatment can be. Antiretroviral therapy works by keeping the amount of virus in the blood so low that it can't damage the immune system and can't be transmitted to others — but that suppression depends on maintaining a steady concentration of the drug in the body. Skip enough doses, and viral levels can rebound, giving the virus room to mutate into drug-resistant strains that are harder — sometimes impossible — to treat with existing medications.
For some patients, remembering a daily pill is no different than brushing their teeth. But for millions of others, daily adherence collides with real life: unstable housing, mental health struggles, substance use, the sheer psychological weight of a visible daily reminder of an HIV diagnosis, or simply the logistics of accessing refills in regions with strained healthcare infrastructure. Public health researchers have long identified adherence — not drug efficacy — as the single biggest barrier to viral suppression at a population level, particularly in the low- and middle-income countries that carry the heaviest burden of the global HIV epidemic.
That's precisely why researchers and advocates present at AIDS 2026 have framed the once-weekly pill as more than an incremental convenience. Fewer doses per month means fewer opportunities to miss one, fewer daily reminders of a diagnosis some patients still find stigmatizing to manage in front of family, roommates or coworkers, and — crucially — the possibility of dramatically reduced treatment costs and logistical burden for health systems that currently have to manufacture, ship, distribute and track a pill for every single day of the year, for every patient.
The Bigger Picture: A Year of HIV Breakthroughs
The once-weekly pill lands amid a broader wave of momentum in HIV science. Lenacapavir itself, in its injectable form, was hailed as a landmark breakthrough as a twice-yearly prevention shot capable of providing near-total protection against HIV infection in previous large-scale trials — a result public health officials described as one of the most important prevention tools since the epidemic began. Researchers have separately been racing to develop a durable HIV vaccine, with a different team recently reporting the strongest antibody response ever recorded in animal studies using a "germline-targeting" vaccine strategy, though that approach remains in early human trials and is a fundamentally different tool than a treatment pill for people already living with the virus.
Together, these advances point to a strategy public health experts have pushed for years: attacking HIV from every angle simultaneously, using prevention shots for the uninfected, simplified treatment regimens for those living with the virus, and a vaccine as the long-term goal that could someday end the epidemic outright. A once-weekly treatment pill doesn't replace any of those efforts — but it could dramatically ease the day-to-day burden on the roughly 40 million people currently living with HIV worldwide, according to global health estimates, while research toward a cure and a vaccine continues.
What This Means for You
If you or someone you love is living with HIV, this is not yet a drug you can ask your doctor to prescribe — islatravir/lenacapavir remains investigational, and Gilead and Merck will need to complete their trials, submit the full dataset to regulators, and secure approval from agencies like the FDA before it reaches pharmacies. That process typically takes at least a year or more after positive Phase 3 results, assuming no complications arise in the fuller dataset or regulatory review.
In the meantime, current daily and long-acting injectable HIV treatments remain highly effective, and patients should not alter their existing regimen based on this news without talking to their doctor first. But for patients who have struggled with the psychological or logistical weight of a daily pill, this is a genuine reason for hope: a treatment that could soon ask patients to remember their HIV medication only 52 times a year instead of 365.
For the broader public, the development is also a reminder of how far HIV treatment has come from the darkest days of the epidemic in the 1980s and 1990s, when an HIV diagnosis was effectively a death sentence. Today, appropriately treated HIV is a manageable chronic condition, and the frontier of research is no longer just "can we keep patients alive" but "how much can we shrink the burden of staying alive."
The Bottom Line
A once-a-week pill sounds like a modest change on paper. In practice, doctors and advocates at AIDS 2026 say it represents exactly the kind of unglamorous, practical innovation that could move the needle on a global epidemic more than any single dramatic breakthrough — because the biggest obstacle to ending HIV as a public health threat was never just the virus. It was the sheer difficulty of asking millions of people to take a pill, without fail, every day, for the rest of their lives. If regulators eventually agree with what the ISLEND trials found, that ritual may soon be a thing of the past.
Full results from the ISLEND-1 and ISLEND-2 trials are expected to be presented in detail at late-breaking sessions during AIDS 2026 this week in Rio de Janeiro.
